With his interests in IP development, biotechnology innovation policy, and R&D, Luiz Otávio Pimentel, president of Brazil’s patent office, tells LSIPR of his aims to improve the country’s IP performance.
Under the guidance of Luiz Otávio Pimentel, Brazil’s IP landscape has gone through significant changes in recent years.
Since his appointment as president of the Brazilian Patent and Trademark Office (INPI) in 2015, Pimentel has already made an impact.
Bringing with him interests in IP development, biotechnology innovation policy, and research and development projects, Pimentel is ideally placed to steer Brazil into clear IP waters.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Luiz Otávio Pimentel, R&D, Brazilian Patent and Trademark Office, INPI, Brazilian Health Regulatory Agency, ANVISA, LSIPR 50 2018